Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353936 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2HDAC1HTR1AHTR7HTR6 | |
| SCHEMBL13330197 | 0.88 | LMNA (0.39) | SMN1; SMN2HTR1AMEN1KMT2ANPSR1 | |
| SCHEMBL13330232 | 0.88 | LMNA (0.39) | SMN1; SMN2HTR1AMEN1KMT2ANPSR1 | |
| SCHEMBL354128 | 0.86 | GABBR2 (0.42) | SMN1; SMN2HTR1AHTR7HTR6MEN1 | |
| SCHEMBL353073 | 0.86 | GABBR2 (0.42) | SMN1; SMN2HTR1AHTR7HTR6MEN1 | |
| SCHEMBL355588 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4ELMNACYP1A2 | |
| SCHEMBL6009922 | 0.86 | HTT (0.43) | HTR1AHTR7HTR6KDM4EMEN1 | |
| SCHEMBL6009898 | 0.86 | HTT (0.43) | HTR1AHTR7HTR6KDM4EMEN1 | |
| SCHEMBL355152 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4ELMNACYP1A2 | |
| SCHEMBL6009893 | 0.86 | HTT (0.43) | HTR1AHTR7HTR6KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | SMN1; SMN2 38/4885HDAC1 3833/4885HTR1A 3279/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885HDAC1 3758/4885HTR1A 2510/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885HDAC1 3758/4885HTR1A 2510/4885 |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885HDAC1 3758/4885HTR1A 2510/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 77/4885HDAC1 4188/4885HTR1A 2489/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885HDAC1 3758/4885HTR1A 2510/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885HDAC1 3758/4885HTR1A 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.